Merck Kgaa (MKGAF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

gentlemen welcome to the Merck investor and analyst conference call on first quarter 2025 as a reminder all participants will be in a listen-only mode I am now handing over to Florian Schrader head of investor relations who will lead you through this conference please go ahead sir thank you so much Heidi and a very warm welcome to this Merck q125 results call My name is Florian Schreder. I'm the head of investor relations here at Merck. I'm delighted to be joined today by Belen Garrigio, our group CEO, as well as Helene von Röder, our group CFO. For the Q&A part of this call, we will also have Matthias Heinzel, CEO LifeScience, Jean-Charles Wirth, designated CEO LifeScience, Peter Günther, CEO Healthcare, Danny Barzohar, designated CEO Healthcare, as well as Kai Beckmann, CEO Electronics. In the first couple of minutes of this call, we would like to guide you through the key slides of the presentation. After that, we will be more than happy to take your questions. With this, I would now like to hand over to Belen to start. Thank you, Florian, and welcome everybody from my side to our Q1 earnings call. I am now on slide number five of the presentation, starting with the highlights. First of all, you would agree with me that this quarter was characterized by a rapidly changing global economic landscape, to say the least. And we delivered very solidly, achieving profitable growth across our three business sectors in Q1. Organically, group revenues increased by 3%, and EBITDA P went up by 6%. Healthcare and life science showed the strongest organic sales growth at 3%, while electronic sales were up by 1%. Now, I would like to draw your attention to the highlight of the quarter, which is the remarkable progress in process solutions that is crossing to the double-digit gro...